Skip to main content

Author: Péter Sárosi

Péter Sárosi is the Executive Director of the Rights Reporter Foundation. He is a human rights activist and drug policy expert, the founder and editor of the Drugreporter website since 2004, the author of countless articles, co-author of books and director of films about harm reduction and drug policy reform. He was the Director of the Drug Policy Program at the Hungarian Civil Liberties Union between 2004 and 2015. He is experienced in working at international drug policy forums such as the Commission on Narcotic Drugs. He was twice elected to the Core Group of the EU Civil Society Forum on Drugs. He is the co-chair of the Eurasian Harm Reduction Network. He has been representing the Hungarian Harm Reduction Network at the government’s drug advisory body in Hungary since 2007. Peter also contributed to building a network of advocacy NGOs in Europe: the European Drug Policy Initiative. He provided technical assistance to several NGOs, and launched several campaigns on drug policy reform. As a member of the Drugreporter video advocacy team, he has produced videos about drug policy issues in a number of countries. These videos are now part of a unique online drug policy video library.

“You Cannot Promote Safety Through Prejudice” – Interview with Marinella Kloka On Harm Reduction in Greece

Marianella Kloka is one of the leading figures of the Greek harm reduction movement, and is currently the advocacy officer at the Praksis NGO. We interviewed her about how the government and civil society in Greece have responded to the threat of an HIV epidemic among people who use drugs. Read her inspiring thoughts, and watch our video about people, drugs and harm reduction in Greece!

Continue reading

“Drugs Are Less of a Political Priority” – Interview with Alexis Goodseel, The Director of the EMCDDA

On 1 January 2016, Alexis Goosdeel became the new Director of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Lisbon, Portugal. In an interview with Drugreporter, he discusses the challenges posed by Europe’s drugs problems, and the future plans and opportunities for the agency in a changing political environment.

Continue reading


©